Although peg-IFN-α-based therapy can help HBeAg-negative chronic HBV carriers achieve faster and better HBV suppression and possibly a clinical cure, thereby reducing the occurrence of end-stage liver disease [20], there are still some patients with a negative response, so the efficacy of peg-IFN-α therapy still needs to be evaluated and optimized. Here, IFNA1 is linked to End Stage Liver Disease.